AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pharmaceutical Companies

831.475

-5.849-0.70%

Number of Gainers:4

Number of Losers:22

Number of Flat:20

PE:- -

High:849.243

Open:837.152

Low:828.985

Close:837.324

Loading ...

Broker laments 'catastrophic negative surprise' that highlights the risks with these types of ASX shares

ASX 200 plunges as US tariffs fall-out continues

This ASX share potentially 'has no value from here', says broker

Friday’s HotCopper Trends: Mesoblast dodges tariffs, Orthocell’s FDA tick | April 4, 2025

The Market Herald

BUZZ-Australia's Orthocell rises on FDA nod for US launch of nerve repair drug

BRIEF-Orthocell Says Got US FDA 510(K) Clearance For Remplir To Commence Commercial Distribution

Why Ansell, Capricorn Metals, Orthocell, and Sonic Healthcare shares are charging higher

BRIEF-Cann Group Seeks Trading Halt

BRIEF-Mesoblast Says Mesoblast Cell Therapy Products Not Subject To U.S. Tariffs

Orthocell Receives US FDA Clearance for Nerve Repair Product; Shares Down 4%

MT Newswires Live

Avita Medical's Cohealyx Wound Treatment Makes Commercial Launch in US; Shares Down 4%

MT Newswires Live

Mesoblast Says Products Exempt From US Tariffs

MT Newswires Live

BRIEF-Mesoblast Says Allogeneic Cell Therapy Products Are Designated ‘U.S. Country Of Origin’ And Not Subject To U.S. Tariffs

Mesoblast Allogeneic Cell Therapy Products Are Designated ‘U.S. Country of Origin’ and Not Subject to U.S. Tariffs

THOMSON REUTERS

Is CSL the most defensive ASX stock on the market?

Mesoblast Ltd - Cell Therapy Products Not Subject to U.S. Tariffs

THOMSON REUTERS

Mesoblast - Allogeneic Cellular Products, Including Ryoncil and Revascor, Will Not Be Subject to Tariffs

THOMSON REUTERS

Orthocell - Received US FDA 510(K) Clearance for Remplir to Commence Commercial Distribution in US Market

THOMSON REUTERS

This company has entered a trading halt, is it about to announce FDA approval?

ASX Market Open: Oz caught up as Trump tariffs stoke recession panic, lead to $4B Wall Street wipeout | April 4, 2025

The Market Herald

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK7508/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK7508","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"Pharmaceutical Companies","latestPrice":831.4746,"timestamp":1743742799957,"preClose":837.3237,"halted":0,"volume":83711983,"delay":0,"changeRate":-0.006985,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":-5.849121,"latestTime":"04-04 16:00:00 AEDT","open":837.1523,"high":849.2428,"low":828.9854,"amount":301894206,"amplitude":0.024193,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1743984000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1743721200000,1743742800000]],"turnoverRate":0.002297,"increases":5,"decrements":26,"flats":13,"marketCap":133786707862.75,"floatMarketCap":131123270782.1875},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","high":849.2428,"amplitude":0.024193,"preClose":837.3237,"low":828.9854,"latestPrice":831.4746,"volume":83711983,"delay":0,"open":837.1523,"prevYearClose":936.801,"prevWeekClose":826.811,"prevMonthClose":815.605,"prevQuarterClose":815.605,"fiveDayClose":826.811,"twentyDayClose":856.387,"sixtyDayClose":954.206,"secType":"PLATE","market":"AU","turnoverRate":0.002297,"marketCap":133786707862.75,"floatMarketCap":131123270782.1875,"timestamp":1743742799957,"nameCN":"Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7508\",,,,undefined,":{"bkCode":"BK7508","up":4,"down":22,"flat":20},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7508\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2525222758","title":"Broker laments 'catastrophic negative surprise' that highlights the risks with these types of ASX shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2525222758","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525222758?lang=en_us&edition=fundamental","pubTime":"2025-04-05 04:00","pubTimestamp":1743796800,"startTime":"0","endTime":"0","summary":"ASX share Opthea Limited (ASX: OPT)remains suspended from trading as the biotechcompany works to avoid insolvency.  Opthea last traded at 60 cents per share.   Last week, we learned that Opthea has de","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/05/broker-laments-catastrophic-negative-surprise-that-highlights-the-risks-with-these-types-of-asx-shares/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7511","MSB.AU","BK7067","BK7508","CSL.AU","OPT.AU","BK4139","OPT","XJO.AU","BK7501"],"gpt_icon":0},{"id":"2524279082","title":"ASX 200 plunges as US tariffs fall-out continues","url":"https://stock-news.laohu8.com/highlight/detail?id=2524279082","media":"MotleyFool","labels":["economic"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524279082?lang=en_us&edition=fundamental","pubTime":"2025-04-04 14:00","pubTimestamp":1743746431,"startTime":"0","endTime":"0","summary":"The S&P/ASX 200 Index  plummeted by 191.9 points or 2.44% on Friday to finish the week at 7,667.8 points.Uncertainty about how the newly announced reciprocal US tariffs will impact ASX 200 shares fuelled today's dive.Based on closing values, today's market rout has pushed the ASX 200 into an official market correction.A market correction is defined as a major index falling 10% from its most recent peak.The ASX 200 narrowly avoided a correction last month after it fell 9.43% from its record high on 14 February to a trough on 13 March.The fall saw several blue-chip sharestrading at multi-year lows, including Fortescue Ltd  and CSL Ltd .The ASX 200 began a rebound on 14 March, but this week's US tariffs news has brought that undone.The ASX 200 closed down 10.38% from its 14 February high today.Today, we heard from more companies about the potential impact of the tariffs on their operations.ASX 200 dives into official correction as more companies reveal US tariff impact. The ASX 200 biotec","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/04/asx-200-plunges-as-us-tariffs-fall-out-continues/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"economic","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["AOV.AU","BK7508","CSL.AU","BK7129","FMG.AU","ANN.AU","BRG.AU","BK7067","BK7511","MSB.AU","BK7501","BK7051","BK7126","BK7507","XJO.AU","BK7119"],"gpt_icon":0},{"id":"2524227858","title":"This ASX share potentially 'has no value from here', says broker","url":"https://stock-news.laohu8.com/highlight/detail?id=2524227858","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524227858?lang=en_us&edition=fundamental","pubTime":"2025-04-04 12:55","pubTimestamp":1743742507,"startTime":"0","endTime":"0","summary":"The ASX biotech advised investors on 24 March that its Phase 3 COAST clinical trial of OPT-302 had failed to meet its primary endpoint.  The trial was assessing sozinibercept  combined with aflibercept to treat wet AMD. The failure of the trial raised serious financial concerns for Opthea. The company said it would review its obligations under its Development Funding Agreement  with key investors to decide the next steps.  What's the latest news with this ASX biotech share?Importantly, Opthea and its DFA investors have agreed that ceasing both trials does not constitute a 'termination event' under the DFA. This means Opthea does not","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/04/this-asx-share-potentially-has-no-value-from-here-says-broker/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK4573","BK4566","LU0198837287.USD","BK4139","OPT","LU1803068979.SGD","LU0823434740.USD","LU1951200564.SGD","BK7508","LU0979878070.USD","LU0390134368.USD","LU0719512351.SGD","BK4534","BK4575","LU1989764664.SGD","LU2458330243.SGD","IE00BMPRXR70.SGD","BK4585","BK4588","LU1064131342.USD","LU2054465674.USD","IE00B5949003.HKD","BK4529","OPT.AU","LU1303367103.USD","LU0127658192.USD","LU2458330169.SGD","LU1880398471.USD","BK4605","BK7067","LU1988902786.USD","LU2360106780.USD","LU0109392836.USD","LU1242518931.SGD","LU1316542783.SGD","LU0823434583.USD","LU1951198990.SGD","BK4612","LU0642271901.SGD","LU0056508442.USD","BK4512","LU1852331112.SGD","IE0009356076.USD","LU0082616367.USD","LU0823421333.USD","BK4141","GFS","IE0004445239.USD","LU2264538146.SGD"],"gpt_icon":1},{"id":"2524478612","title":"Friday’s HotCopper Trends: Mesoblast dodges tariffs, Orthocell’s FDA tick | April 4, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2524478612","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524478612?lang=en_us&edition=fundamental","pubTime":"2025-04-04 09:57","pubTimestamp":1743731820,"startTime":"0","endTime":"0","summary":"The ASX has been down 1.5% at 7,739 points this morning.There’s been carnage on the ASX and the Energy sector has been enduring a bloodbath, followed by IT and Utilities.Staples and Health Care are the only sectors in positive territory so far.In company news, Mesoblast  has been among the most watched on HotCopper forums today after the medicinal company confirmed its belief its products will not be subject to United States tariffs.Orthocell  has also been trending on news the US FDA has given the green light for the company’s nerve repair product, Remplir, to be sold in the States.And, finally, Bellevue Gold  has provided an update saying it’s not yet in a position to make an announcement about the potential downward adjustment to its FY25 production guidance.Levy beef: Trump whacks Oz with 10% tariffs on “Liberation Day”。The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/fridays-hotcopper-trends-mesoblast-dodges-tariffs-orthocells-fda-tick-april-4-2025-2025-04-04/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["OCC.AU","BK7508","BK7067","BK4139","MESO","MSB.AU","BK7501","BGL.AU","BK7104"],"gpt_icon":0},{"id":"2524425712","title":"BUZZ-Australia's Orthocell rises on FDA nod for US launch of nerve repair drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2524425712","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524425712?lang=en_us&edition=fundamental","pubTime":"2025-04-04 09:49","pubTimestamp":1743731350,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Orthocell rises on FDA nod for US launch of nerve repair drug** Orthocell OCC.AX jumps 7% to A$1.53; set for biggest intraday percentage gain since March 17** Biotech firm receives U.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250404:nL3N3QI02L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OCC.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2524242328","title":"BRIEF-Orthocell Says Got US FDA 510(K) Clearance For Remplir To Commence Commercial Distribution","url":"https://stock-news.laohu8.com/highlight/detail?id=2524242328","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524242328?lang=en_us&edition=fundamental","pubTime":"2025-04-04 09:47","pubTimestamp":1743731256,"startTime":"0","endTime":"0","summary":"BRIEF-Orthocell Says Got US FDA 510(K) Clearance For Remplir To Commence Commercial DistributionApril 4 (Reuters) - Orthocell Ltd OCC.AX:RECEIVED US FDA 510(K) CLEARANCE FOR REMPLIR TO COMMENCE COMMER","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250404:nFWN3QH0LZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","OCC.AU"],"gpt_icon":0},{"id":"2524924232","title":"Why Ansell, Capricorn Metals, Orthocell, and Sonic Healthcare shares are charging higher","url":"https://stock-news.laohu8.com/highlight/detail?id=2524924232","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524924232?lang=en_us&edition=fundamental","pubTime":"2025-04-04 09:37","pubTimestamp":1743730655,"startTime":"0","endTime":"0","summary":"TheS&P/ASX 200 Index(ASX: XJO) is having a tough finish to the week. In afternoon trade, the benchmark index is down 1.45% to 7,743.4 points. Four ASX shares that are not letting that hold them back a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/04/why-ansell-capricorn-metals-orthocell-and-sonic-healthcare-shares-are-charging-higher/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7508","BK4516","XJO.AU","IE0004086264.USD","BK4552","LU0061475181.USD","LU1791807156.HKD","LU2237443978.SGD","LU1868836757.USD","LU0106831901.USD","LU2237443549.SGD","CMM.AU","BK4585","BK7126","BK7124","LU2471134879.HKD","LU2750360997.AUD","LU2471134796.USD","LU0048573561.USD","LU0251131958.USD","LU0742534661.SGD","BK7104","LU1868837136.USD","LU2237438978.USD","BK4137","BK4504","LU1668664300.SGD","LU2237443465.HKD","IE0004091025.USD","HCSG","IE00BFXG1179.USD","LU1868836914.USD","SHL.AU","OCC.AU","IE00B19Z3581.USD","IE0034235188.USD","LU2237443622.USD","IE0002270589.USD","IE00B19Z3B42.SGD","ANN.AU","BK4533","LU0251142724.SGD","LU2471134952.CNY","LU2471134523.USD","LU2237443895.HKD","BK4588","BK4550","LU2750360641.GBP","IE00BSNM7G36.USD","BK4127"],"gpt_icon":0},{"id":"2524245428","title":"BRIEF-Cann Group Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2524245428","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524245428?lang=en_us&edition=fundamental","pubTime":"2025-04-04 08:16","pubTimestamp":1743725767,"startTime":"0","endTime":"0","summary":"BRIEF-Cann Group Seeks Trading HaltApril 4 (Reuters) - Cann Group Ltd CAN.AX:SEEKS TRADING HALT PENDING ANNOUNCEMENT ON CAPITAL RAISINGFurther company coverage: CAN.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250404:nFWN3QH1H7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7502","CAN.AU","BK7508","BK7096"],"gpt_icon":0},{"id":"2524124544","title":"BRIEF-Mesoblast Says Mesoblast Cell Therapy Products Not Subject To U.S. Tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2524124544","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524124544?lang=en_us&edition=fundamental","pubTime":"2025-04-04 08:15","pubTimestamp":1743725743,"startTime":"0","endTime":"0","summary":"BRIEF-Mesoblast Says Mesoblast Cell Therapy Products Not Subject To U.S. TariffsApril 4  - Mesoblast Ltd MSB.AX:MESOBLAST CELL THERAPY PRODUCTS NOT SUBJECT TO U.S. TARIFFSCELL THERAPY PRODUCTS NOT SUBJECT TO U.S. TARIFFSALLOGENEIC CELLULAR PRODUCTS, INCLUDING RYONCIL AND REVASCOR, WILL NOT BE SUBJECT TO TARIFFSFurther company coverage: MSB.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250404:nFWN3QH173:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK7501","MSB.AU","BK7508","MESO","BK7067"],"gpt_icon":0},{"id":"2524243038","title":"Orthocell Receives US FDA Clearance for Nerve Repair Product; Shares Down 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2524243038","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524243038?lang=en_us&edition=fundamental","pubTime":"2025-04-04 08:00","pubTimestamp":1743724841,"startTime":"0","endTime":"0","summary":"Orthocell  received regulatory clearance from the US Food and Drug Administration for its nerve repair product, Remplir, under the 510 pathway, allowing sales in the US market, according to a Friday filing with the Australian bourse.Products delivered to the US will be manufactured at the company's Western Australia facility, the filing said.Remplir is approved for sale in Australia, New Zealand, and Singapore, with pending approvals in Canada and Thailand in the next six months, according to the filing.Shares were down 4% in morning trade Friday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XAO.AU","XKO.AU","BK7508","XJO.AU","BK7067","OCC.AU"],"gpt_icon":0},{"id":"2524487472","title":"Avita Medical's Cohealyx Wound Treatment Makes Commercial Launch in US; Shares Down 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2524487472","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524487472?lang=en_us&edition=fundamental","pubTime":"2025-04-04 07:36","pubTimestamp":1743723362,"startTime":"0","endTime":"0","summary":"Avita Medical  launched wound care treatment Cohealyx in the US, according to a Friday filing with the Australian bourse.Cohealyx is a collagen-based dermal matrix branded by Avita Medical and co-developed with Regenity Biosciences, the filing stated. It is designed to provide wound bed through cellular migration and revascularization for faster closure.Avita Medical is enrolling participants in the Cohealyx I post-market trial.The company's shares were down almost 4% in recent Friday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7067","AVH.AU"],"gpt_icon":0},{"id":"2524248874","title":"Mesoblast Says Products Exempt From US Tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2524248874","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524248874?lang=en_us&edition=fundamental","pubTime":"2025-04-04 07:14","pubTimestamp":1743722066,"startTime":"0","endTime":"0","summary":"Mesoblast  said that its allogeneic cellular products will not be impacted by the US government's recently implemented tariffs on imported goods, according to a Friday filing with the Australian bourse.The company clarified that these products are derived from US donors and are classified as US-origin, making them exempt from the tariffs.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7501","XAO.AU","BK4139","BK7067","BK7508","XJO.AU","XKO.AU","MESO","MSB.AU"],"gpt_icon":0},{"id":"2524210636","title":"BRIEF-Mesoblast Says Allogeneic Cell Therapy Products Are Designated ‘U.S. Country Of Origin’ And Not Subject To U.S. Tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2524210636","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524210636?lang=en_us&edition=fundamental","pubTime":"2025-04-04 07:00","pubTimestamp":1743721201,"startTime":"0","endTime":"0","summary":"BRIEF-Mesoblast Says Allogeneic Cell Therapy Products Are Designated ‘U.S. Country Of Origin’ And Not Subject To U.S. TariffsApril 3 (Reuters) - Mesoblast Ltd MSB.AX:MESOBLAST ALLOGENEIC CELL THERAPY ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250403:nFWN3QH1H5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK4139","BK7508","BK7067","MSB.AU","MESO"],"gpt_icon":0},{"id":"2524217028","title":"Mesoblast Allogeneic Cell Therapy Products Are Designated ‘U.S. Country of Origin’ and Not Subject to U.S. Tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2524217028","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524217028?lang=en_us&edition=fundamental","pubTime":"2025-04-04 06:59","pubTimestamp":1743721140,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250403:nFWN3QH1H5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MESO","BK7501","BK7067","BK7508","BK4139","MSB.AU"],"gpt_icon":0},{"id":"2524241549","title":"Is CSL the most defensive ASX stock on the market?","url":"https://stock-news.laohu8.com/highlight/detail?id=2524241549","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524241549?lang=en_us&edition=fundamental","pubTime":"2025-04-04 06:59","pubTimestamp":1743721140,"startTime":"0","endTime":"0","summary":"Searching for a defensive stock to add to your portfolio?CSL Ltd  shares could be an option. What is a defensive stock?Defensive stocks are shares in  mature, dividend-paying companies. These companies also have a record of consistent profits regardless of the state of the broader economy.  Investors often associate them with industries like consumer staples, healthcare, utilities, and some food and beverage businesses – particularly fast-food chains. Demand for these products and services typically remains high even during an economic downturn. In the case of CSL, a global biotechnology company producing medicines and vaccines, it can be considered a defensive stock. This is because medicine and healthcare are essentials that people need to access regardless of economic conditions. Global uncertainty No stock is immune to the ebbs and flows of the global economy. After a rough 2025 so far for many portfolios, it's not outrageous to assume many investors will be looking towards defensi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/04/is-csl-the-most-defensive-asx-stock-on-the-market/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7067","LU0728928796.USD","BK7511","LU1169589451.USD","SG9999004303.SGD","LU1169590202.USD","CSL","SGXZ23171101.USD","CSL.AU","BK7501","BK4086","BK7508"],"gpt_icon":0},{"id":"2524217359","title":"Mesoblast Ltd - Cell Therapy Products Not Subject to U.S. Tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2524217359","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524217359?lang=en_us&edition=fundamental","pubTime":"2025-04-04 06:33","pubTimestamp":1743719606,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250403:nFWN3QH173:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","MSB.AU","MESO","BK4139","BK7508","BK7501"],"gpt_icon":0},{"id":"2524173542","title":"Mesoblast - Allogeneic Cellular Products, Including Ryoncil and Revascor, Will Not Be Subject to Tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2524173542","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524173542?lang=en_us&edition=fundamental","pubTime":"2025-04-04 06:33","pubTimestamp":1743719606,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250403:nFWN3QH173:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK4139","BK7067","BK7508","MSB.AU","MESO"],"gpt_icon":0},{"id":"2524621226","title":"Orthocell - Received US FDA 510(K) Clearance for Remplir to Commence Commercial Distribution in US Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2524621226","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524621226?lang=en_us&edition=fundamental","pubTime":"2025-04-04 06:24","pubTimestamp":1743719079,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250403:nFWN3QH0LZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","OCC.AU"],"gpt_icon":0},{"id":"2524724363","title":"This company has entered a trading halt, is it about to announce FDA approval?","url":"https://stock-news.laohu8.com/highlight/detail?id=2524724363","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524724363?lang=en_us&edition=fundamental","pubTime":"2025-04-04 05:56","pubTimestamp":1743717416,"startTime":"0","endTime":"0","summary":"Given the timeline and the current trading halt, it is highly possible that Orthocell has received the FDA's decision and is preparing to announce the outcome. If the FDA has granted 510 clearance, Orthocell will be authorised to commence commercial distribution of Remplir in the U.S. This would mean access to the substantial U.S. nerve repair market. If the clearance was not granted, the company may need to address the FDA's concerns before proceeding. Following a trading halt, If the halted stock resumes trading with good news, such as FDA approval , investor demand usually drives up the share price. Investors should keep an eye out for further announcements which, based on the media release, could come as early as today.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/04/this-company-has-entered-a-trading-halt-is-it-about-to-announce-fda-approval/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7067","BK7508","OCC.AU"],"gpt_icon":0},{"id":"2524243651","title":"ASX Market Open: Oz caught up as Trump tariffs stoke recession panic, lead to $4B Wall Street wipeout | April 4, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2524243651","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524243651?lang=en_us&edition=fundamental","pubTime":"2025-04-04 05:33","pubTimestamp":1743715980,"startTime":"0","endTime":"0","summary":"Australian shares will plunge on Friday morning when the trading bell rings in Sydney, with ASX 200 futures pointing to a 1.4% nosedive to end Week 14.Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.The impending red bloodbath comes after – you guessed it – tariffs posturing.Trump unveiled his “Liberation Day” tariffs early yesterday morning ; since then, there has been a flurry of responses. China and the European Union especially threatened to strike back against the U.S. levies with their own.The whole thing has sparked sharp fear in U.S. and global markets alike, with many now tipping things to spiral into a global recession quite quickly.The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decis","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-open-oz-caught-up-as-trump-tariffs-stoke-recession-panic-lead-to-4b-wall-street-wipeout-april-4-2025-2025-04-04/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7021","BK7067","BK7501","CTT.AU","BK7049","CSL.AU","BK7508","BK7511","BK7142","WDS.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":1,"totalSize":136}]}}